| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N1-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-742 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-07 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-742
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2022-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2022-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-114806958-B |
| titleOfInvention |
Stomach-derived Bacillus coagulans BCF-01 and its application |
| abstract |
The invention discloses a stomach-derived bacillus coagulans (Weizmannia coagulans) BCF‑01 and an application thereof. The preservation number of the stomach-derived bacillus coagulans (Weizmannia coagulans) BCF‑01 is GDMCC62386. The inventors of the present invention screened a stomach-derived Bacillus coagulans (Weizmannia coagulans) BCF-01 from the gastric mucosal tissue of healthy people. GSE-1 cells have strong adhesion properties, can be effectively used to inhibit the growth of Helicobacter pylori, prevent and/or effectively inhibit Helicobacter pylori-associated gastritis, and have no obvious side effects. |
| priorityDate |
2022-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |